Overview

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
This first-in-human Phase 1 study will be a multicenter, dose-escalating, single-agent study conducted in patients with advanced CD20-associated hematological cancers for which the investigator determines there to be no other higher priority therapies available.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Conjupro Biotherapeutics, Inc.